|
Phase I/II Trial of Imatinib Mesylate; (GLEEVEC; STI571) in Treatment of Recurrent
Oligodendroglioma and Mixed Oligoastrocytoma (NCCTG N0272):
- Pathological confirmation of grade 2-4 Oligodendroglioma and Mixed Oligoastrocytoma
- Evidence of tumor progression by MRI or CT
- 12 weeks since completion of radiation therapy
A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme. (Celldex CDX 110-003):
- Pathological diagnosis of Glioblastoma Multiforme
- Surgery, followed by conventional chemoradiation without progression of disease prior to randomization
|
